NCT01287598 - BAY73-4506 Probe Substrate Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 2, 2011

Primary Completion Date

July 3, 2018

Study Completion Date

July 30, 2018

Conditions

Neoplasms

Interventions

DRUG

Regorafenib (Stivarga, BAY73-4506)

BAY73-4506 administered once a daily (od) in a 21-day on / 7-day off schedule

DRUG

Warfarin

CYP 2C9 (warfarin) at Cycle 1

DRUG

Omeprazole

CYP 2C19 (omeprazole) at Cycle 1

DRUG

Midazolam

CYP 3A4 (midazolam) at Cycle 1

DRUG

Rosiglitazone

CYP2C8 (rosiglitazone) at Cycle 1

Trial Locations (4)

Cross Cancer Institute, Edmonton

British Columbia Cancer Agency-Vancouver Centre, Vancouver

Juravinski Cancer Centre, Hamilton

Sir Mortimer B. Davis Jewish General Hospital, Montreal